- Home
- CDRE vs IOVA Comparison
CDRE vs IOVA Comparison
Compare CDRE & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDRE
- IOVA
- Stock Information
- Founded
- CDRE 2012
- IOVA 2007
- Country
- CDRE United States
- IOVA United States
- Employees
- CDRE N/A
- IOVA N/A
- Industry
- CDRE Industrial Specialties
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CDRE Health Care
- IOVA Health Care
- Exchange
- CDRE Nasdaq
- IOVA Nasdaq
- Market Cap
- CDRE N/A
- IOVA 1.0B
- IPO Year
- CDRE 2021
- IOVA N/A
- Fundamental
- Price
- CDRE $30.45
- IOVA $3.51
- Analyst Decision
- CDRE Strong Buy
- IOVA Strong Buy
- Analyst Count
- CDRE 1
- IOVA 9
- Target Price
- CDRE $37.00
- IOVA $18.22
- AVG Volume (30 Days)
- CDRE 256.1K
- IOVA 10.2M
- Earning Date
- CDRE 05-06-2025
- IOVA 05-08-2025
- Dividend Yield
- CDRE 1.24%
- IOVA N/A
- EPS Growth
- CDRE N/A
- IOVA N/A
- EPS
- CDRE 0.90
- IOVA N/A
- Revenue
- CDRE $567,561,000.00
- IOVA $164,070,000.00
- Revenue This Year
- CDRE $8.19
- IOVA $182.20
- Revenue Next Year
- CDRE $8.18
- IOVA $62.10
- P/E Ratio
- CDRE $33.83
- IOVA N/A
- Revenue Growth
- CDRE 17.62
- IOVA 13698.99
- 52 Week Low
- CDRE $27.07
- IOVA $2.70
- 52 Week High
- CDRE $40.28
- IOVA $14.23
- Technical
- Relative Strength Index (RSI)
- CDRE 49.00
- IOVA 51.94
- Support Level
- CDRE $29.09
- IOVA $2.89
- Resistance Level
- CDRE $30.67
- IOVA $3.43
- Average True Range (ATR)
- CDRE 1.41
- IOVA 0.32
- MACD
- CDRE 0.17
- IOVA 0.09
- Stochastic Oscillator
- CDRE 71.28
- IOVA 86.17
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.